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Lung tumor metabolism is severely altered involving
enhanced levels of glucose uptake, glycolysis, lipogenesis
and protein synthesis. These events are essential for the
support of enhanced energy demands and increased
need for ribonucleotides, proteins and membrane
biogenesis that are required for rapid proliferation.
Combined treatment with cytotoxic therapy and
metabolism modulating agents may improve outcomes
in NSCLC. We observed that radiotherapy (RT) alone
activates the metabolic stress sensor AMP-activated ki-
nase (AMPK) within an Ataxia Telengiectasia Mutated
(ATM) – AMPK – p53/p21cip1 pathway to mediate the
RT-induced G2-M checkpoint and cytotoxicity. Further,
inhibition of biosynthetic pathways and energy produc-
tion through blockade of OxPhos inhibits tumor growth.
In human NSCLC cells and xenografts, we combined RT
with the anti-diabetic agent metformin, which blocks
OxPhos complex I, and showed that metformin activates
the ATM-AMPK-p53/p21cip1 axis and inhibits the Akt-
mTOR-4EBP1 pathway, tumor growth and angiogenesis
and induces apoptosis and radio-sensitization.
Based on these observations and supporting retrospec-
tive clinical evidence from locally advanced lung cancer
patients treated with Chemo-RT, we launched phase II
studies combiningmetforminwith chemo-RT. NRG-LU001
(NCT02186847) and OCOG ALMERA (NCT02186847)
are on-going randomized phase II studies investigating
whether targeting metabolism with metformin can
improve progression free survival in stage III NSCLC.
In recent studies we observed that combined treat-
ment with metabolism modulating agents can enhance
anti-tumor activity in NSCLC. Combined treatment with
Metformin and Salicylate, which activate AMPK through
different mechanisms, mediated increased inhibition of
clonogenic survival in part through AMPK and sup-
pression of de-novo lipogenesis. Further, in earlier
studies we showed that blockade of the cholesterol
synthesis pathway with lovastatin (HMG-CoA reductase
inhibitor) mediated activation of AMPK, suppression ofthe Akt-PI3k pathways and radio-sensitization of
NSCLC.
In current studies we observe that lovastatin also ac-
tivates the ATM-AMPK-p53 axis, inhibit the Akt-mTOR
pathway and mediate tumor suppression in an AMPK-
dependent manner through suppression of de novo
lipogenesis along both the mevalonate and the fatty acid
synthesis pathways. Further, in retrospective clinical
studies we ﬁnd that in locally advanced NSCLC patients
treated with Chemo-RT, statin treatment is associated
with increased survival.
These observations suggest that targeting tumor
metabolism is promising in NSCLC to improve outcomes
of standard cytotoxic therapy. Completion of on-going
trials with metformin will provide the ﬁrst prospective
evidence on this concept. We plan to investigate com-
binations of well-tolerated metabolism modulating
agents that show promising pre-clinical activity in future
rolling phase II studies.
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LA-NSCLC is frequently unresectable and is treated with
concurrent chemo-radiotherapy (CRT), which is fairly
toxic and provides poor disease control and overall
survival. There is an urgent need to develop sensitizers
to cytotoxic therapy that could improve the therapeutic
ratio in this disease.
Preclinical studies from our group and others demon-
strated that the biguanide metformin has activity in lung
cancer and sensitizes lung cancer cells and tumors to
radiotherapy and chemotherapy. Metformin is known to
induce in cells a state of mild metabolic stress through
blockade of the mitochondria OxPhos complex I. We
showed that metformin alone triggers activation of the
ATM-AMP-kinase-p53/p21cip1 pathway, inhibition of the
radio-resistance Akt-mTOR pathway, radio-sensitizes
NSCLC, enhances apoptosis and inhibits angiogenesis.
Metformin is an economical and effective anti-diabetic
agent that is well-tolerated by non-diabetics too. Based
on our pre-clinical results and additional supporting
retrospective data from stage III NSCLC patients treated
with chemo-radiotherapy, we launched a phase II clinical
trial in locally advanced NSCLC combining metformin
with concurrent CRT.
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trial (NCT02186847) is a Canadian multicenter ran-
domized phase II trial funded by the Canadian Institute
for Health Research, which is designed to examine
whether metformin has chemo-radio-sensitization ac-
tivity as well as activity as a single agent in advanced
localized NSCLC. A total of 94 patients will be random-
ized in this screening trial to standard CRT with or
without treatment with 2000mg of metformin, which is
delivered during CRT (2 cycles of cisplatin based
chemotherapy, concurrent with chest RT of 63 Gy in 30
fractions) but continues also as a single agent for a total
of 12 months.
ALMERA is designed to detect a 20% improvement in
lung cancer progression free survival at 12 months. This
trial is now open in several centers across Canada. The
primary outcome is 12 month Progression Free Survival
(PFS) and secondary outcomes include 1 and 2 y overall
survival (OAS), time to loco-regional progression, distant
progression free survival, adverse events and collection of
biospecimens for biomarker studies. These will involve
investigation of circulating serum and blood cell bio-
markers of metformin activity and tumor biomarkers such
as tumor histology, TP53, LKB1 and K-Rasmutation status.
When completed ALMERAwill provide some of the ﬁrst
prospective evidence on the potential of metformin to
improve the outcomes of standard cytotoxic therapy in
locally advanced NSCLC. Biospecimen collect will allow us
to investigate serum and tumors biomarkers ofmetformin
response. Comparison of the results of ALMERA with
other studies, like NRG-LU001, may be able to provide
evidence on the value of metformin as maintenance
therapy and assist in the design of future phase III trials
with metformin in the setting of locally advanced NSCLC.* Due to unforeseen circumstance, this poster was not presented.An integrative cross-tumors approach
identiﬁes FOSL1 as an oncogene
dependency in KRAS-driven lung
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Fernando Lecanda,1 Silvestre Vicent1 1Center for
Applied Medical Research, Pamplona, Spain, 2Stanford
University, Stanford, CA, 3University of Copenhagen,
Copenhagen, Denmark, 4University of Erlangen-
Nuremberg, Erlangen, GermanyThe KRAS oncogene represents a clinically-relevant
target in human cancers refractory to current thera-
pies. Thus, the identiﬁcation of molecules mediating
oncogenic KRAS effects may help implement novel
therapeutic strategies. Here we describe a new
approach integrating a cross-tumors gene-expression
screen and patient survival information to unveil KRAS
dependencies in human tumors. This strategy uncov-
ered the transcription factor FOS-like antigen 1
(FOSL1) as a critical mediator of KRAS-driven lung
tumors. FOSL1 was up-regulated in mouse and human
mutant KRAS cells and its high expression was a
marker of poor survival in patients harboring KRAS
mutations. Additionally, FOSL1 loss led to impaired
cell viability in mutant KRAS cancer cells in vitro and
in vivo and in a genetically-engineered mouse model of
Kras mutated lung adenocarcinoma. Mechanistically,
this effect involved the transcriptional down-regula-
tion of genes involved in mitosis, a pathway previously
postulated to act orthogonally to KRAS signaling,
whose high expression was associated with shortened
survival of mutant KRAS patients. Lastly, pharmaco-
logical inhibition of FOSL1 downstream targets
involved in mitosis progression had a preferential
deleterious impact on mutant KRAS tumors than wild
type. Collectively, our ﬁndings identify FOSL1 as a
critical factor in KRAS-driven tumors, thereby impli-
cating FOSL1 and downstream targets as potential
candidates for therapeutic intervention.
Supported by a 2015 Young Investigator Award by the
International Association for the Study of Lung Cancer
(IASLC).Intelligent forceps for solitary
pulmonary nodule diagnostics*
Jiri Votruba, Tomas Bruha Charles University
Hospital, Praha, Czech RepublicRecently, SPNs have become more frequently encoun-
tered in pulmonary medicine. Therefore, an efﬁcient and
reliable method for detecting SPNs based on their
morphological characteristics is needed.
We have validated the efﬁcacy of near infrared (NIR)
spectroscopy based catheter connected to biopsy forceps
for solitary pulmonary nodule (SPN) diagnostics.
Methods: Between May 2014 and May 2015 we exam-
ined 20 male and 18 female patients having a median
age of 62 years with positron emission tomography-
computed tomography ﬁndings of metabolically active
SPN between 1, 5 to 3 cm in diameter.
Fluoroscopic guidance was combined with a radial
EBUS (without guide-sheath). In the case radial EBUS
